Vanguard Fiduciary Trust
ALZN icon

Vanguard Fiduciary Trust’s Alzamend Neuro ALZN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Hold
21,020
– – ﹤0.01% 3965
2026
Q1 		$22.3K Buy
+21,020
New +$42K ﹤0.01% 3938

Other funds holding ALZN

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Vanguard Fiduciary Trust's ALZN Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Alzamend Neuro (ALZN) position steady in Q2 2026 at 21,020 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Vanguard Fiduciary Trust first reported a position in ALZN in Q1 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • Vanguard Fiduciary Trust held 21,020 shares of Alzamend Neuro worth $25.2K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Alzamend Neuro share count unchanged in Q2 2026.
  • Alzamend Neuro made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3965 holding.
  • Vanguard Fiduciary Trust first reported a position in Alzamend Neuro in Q1 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.